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Objective: The DIVA study is aimed at setting up a standardized genotypic tropism-testing on proviral-DNA for the rou-
tine clinical diagnostic-laboratory. Methods: Twelve local centres and 5 reference centres (previously cross-validated) were
identified. For inter-center validation-procedure, 60 peripheral-blood mononuclear cells (PBMCs) aliquots from 45
HAART-treated patients were randomly chosen for population V3 sequencing on proviral-DNA at local HIV centre and
at reference-laboratory. Viral tropism was predicted by Geno2Pheno algorithm (False Positive Rate [FPR] = 20%) as pro-
posed by the European-Guidelines. Quantification of total HIV-1 DNA was based on a method described by Viard (2004).
Results:Quantification of HIV-1 DNA was available for 35/45 (77.8%) samples, and gave a median value of 598 (IQR:252-
1,203) copies/106 PBMCs. A total of 56/60 (93.3%) samples were successfully amplified by both the reference and the lo-
cal virological centers. The overall concordance of tropism prediction between local and reference centers was 54/56
(96.4%). Results of tropism prediction by local centers were: 33/54 (61.1%) R5 and 21/54 (38.9%) X4/DM. Conclusion:
There was high concordance in the genotypic tropism prediction based on proviral DNA among different virological cen-
ters throughout Italy. Our results are in line with other European studies, and support the use of genotypic tropism test-
ing on proviral DNA in patients with suppressed plasma HIV-1 RNA candidate to CCR5-antagonist treatment.
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INTRODUCTION
Human immunodeficiency virus type 1 (HIV-1)
entry into host cells requires coordinated inter-
actions of the envelope glycoprotein gp120 with
the CD4 receptor and with one of the chemokine
receptors, CCR5 or CXCR4. Pure CCR5-tropic
and pure CXCR4-tropic virus can use only the
CCR5 and CXCR4 co-receptors to enter target
cells, respectively, while dual-tropic virus can use
both co-receptors (Berger et al., 1998). 
The study of HIV-1 co-receptor usage has patho-
genetic implications due to its strong correlation
with the rate of disease progression in HIV-1 in-
fected individuals (Roeges et al., 2005; Watres et
al., 2008; Raymond et al., 2010). Determining HIV-
1 co-receptor usage is also critical since the CCR5
co-receptor has become the target of a new class of
anti-HIV-1 drugs that specifically inhibit the entry
of CCR5-tropic HIV-1 strains into the target cells
(MacArthur et al., 2008). Maraviroc is the first ap-
proved CCR5 antagonist, that entered clinical prac-
tice in 2007. Assessment of HIV-1 co-receptor us-
age is mandatory for the clinical use of this drug.
Among the different approaches for tropism de-
termination, genotypic population sequencing is
the preferred method in Europe (Vandekerckhove
et al., 2011 European Guidelines for tropism).
The use of maraviroc is recommended for the
treatment of antiretroviral-experienced patients
failing prior regimens. However, the favorable
pharmacokinetic properties and the good safety
profile of this drug can further support its con-
sideration as part of switch or simplification
strategies in drug-treated patients with unde-
tectable plasma HIV-1 RNA. In addition, as
shown in maraviroc clinical trials, a potential im-
mune benefit of maraviroc might encourage its
use as part of intensification strategies in HIV-1-
infected patients with impaired CD4 gains despite
prolonged suppression of HIV replication with
antiretroviral therapy (Cooper et al., 2010).
The determination of HIV-1 co-receptor usage in
patients with undetectable/low level viremia is
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challenging. Two approaches have so far been ex-
plored. The first relies on testing older stored plas-
ma specimens collected before initiation of ART.
An alternative approach might be testing current
proviral DNA collected from peripheral blood
mononuclear cells (PBMCs). Recent data suggest
that using proviral HIV-1 DNA could be an op-
tion in these patients (Seclen et al., 2001; Souliè
et al., 2011).
In this light, the DIVA (DNA Tropism Italian
Validation Concerted Action) study was aimed at
developing a well-standardized genotypic test for
tropism determination in proviral DNA shared
by the Italian scientific community. The avail-
ability of a rapid and cost-effective assay to de-
termine tropism on proviral DNA is crucial to op-
timize the use of CCR5 antagonists in clinical
practice.
METHODS
Structure of the DIVA study: reproducibility
of the test and validation of virological
centers participating to the study
The DIVA study was designed to set up a new pro-
tocol for V3 sequencing on proviral DNA for the
routine clinical diagnostic laboratory. The study
included two consecutive steps. Phase 1 was
aimed at cross-validating the genotypic tropism
test on proviral DNA among the 5 reference cen-
ters involved in the project (University of Rome
“Tor Vergata” , University of Rome “La Sapienza”,
“San Raffaele” Institute, University of Siena,
University of Padova). For this phase, PBMCs
from 8 HAART-treated patients with a HIV-1 RNA
<50 copies/ml from at least 6 months were col-
lected. For each patient, PBMCs were divided in-
to 6 aliquots: 5 containing ~4x106 cells for V3 se-
quencing and tropism prediction, and 1 contain-
ing 106 cells for quantification of total HIV-1 DNA.
The 5 aliquots per patient were processed for V3
sequencing by the 5 reference centers and the re-
sults were then compared. 
Phase 2 was aimed at validating the methodolo-
gy for tropism determination on proviral DNA
among the 12 local virological centers involved
in the project. For this phase, each reference cen-
ter sent to a defined set of local virological centers
PBMCs from 5 distinct patients. For each patient,
PBMCs were divided into 3 aliquots: 2 containing
~4x106 cells for V3 sequencing and tropism pre-
diction, and 1 containing 106 cells for quantifica-
tion of total HIV-1 DNA. The 2 PBMCs aliquots
were processed for V3 sequencing each by the lo-
cal and the reference center, respectively, and re-
sults were then compared. 
For both phase 1 and 2, the validation process
was considered successful if the V3 amino acid
sequences obtained from the same sample
showed a degree of amino acid similarity >80%
and no change in HIV-1 tropism determination
was observed for 4 out of 5 samples tested.
Protocol for tropism determination 
on proviral DNA
Cells. Lympho-monocytic cells were obtained
from the peripheral blood of HIV-1 infected pa-
tients by separation over a Ficoll-Hypaque gradi-
ent as previously described (Aquaro and Perno,
2005).
Quantification of total HIV-1 DNA. To quantify
total HIV-1 DNA in PBMCs, the Real Time
TaqMan protocol published by Viard et al., 2004
was adapted to the Light Cycler (Roche Molecular
Biochemicals, Indianapolis, IN). The cellular line
8E5, containing one copy of HIV-1 DNA inte-
grated for each cell, was used to build a standard
curve of seven dilutions (75,000-37,500-3,750-375-
37.5-3.75-1.87 copies). The sensitivity of PCR is
one copy of HIV-1 DNA per reaction (1 copy per
reaction=13.3 copies/106 PBMCs). The HIV-1
DNA target was hybridized with TaqMan probe
and read on channel F1/F2 of the Light Cycler.
To verify DNA integrity, the reagents of LC control
DNA kit (Roche Molecular Biochemicals) were
used, amplifying a 110-bp fragment of human b-
globin in the same reaction. This second internal
control target was hybridized with FRET probe
and read on channel F3/F2 of the Light Cycler.
To verify the accuracy of the Real Time PCR re-
sult, different HIV-1 DNA standards (AIDS
Research and Reference Reagent Program,
DAIDS, NIAID, NIH: PCR Panel 001 from Dr.
Shirley Kwok and Dr. Cindy Christopherson,
Roche Molecular Systems) were also quantified
(Sarmati et al., 2007).
Sequencing of HIV-1 gp120 V3 domain. HIV-1
DNA was extracted from PBMCs by means of a
commercially available kit (QIAamp DNA Viral
Mini kit, Qiagen) according to the manufactur-
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FIGURE 1 - Location of the V3 loop amplification and sequencing primers on HIV-1 gp120 env coding region.
Primers ENVS10 and AS5 were used for the first PCR reaction. Semi-nested PCR was directed by primers S2 and AS5.
Primers used for sequencing reaction are S6, S5, AS1, and AS3bis.
er’s instructions. The V3-containing region of the
env gene was amplified using the forward primer
ENVS10 5’CCAATTCCCATACATTATTGT 3’ (nu-
cleotide [nt]: 538-558 of HIV-1 gp120 env gene)
and the reverse primer V3AS5 5’CTTCTC-
CAATTGTCCCTCA 3’ (nt: 1292-1310). The condi-
tions for amplification were: one cycle 93°C for 12
min, 40 cycles (93°C 30s, 50°C 30s, 72°C 50s), and
a final step at 72°C for 10 min, using the follow-
ing master mix: 5 ul of Taq buffer 10X, 3 ul of 25
mM MgCl2, 28.95 ul of DNase- and RNase-free
bidistelled water, 0.75 ul of 10 uM primers, 0.8 ul
of 12.5 mM dNTPs, 0.75 ul of Taq (5 u/ul) in a to-
tal volume of 40 ul.
When the first PCR product was not visible in
agarose electrophoresis gels, a semi-nested PCR
was run by using the following PCR primers (de-
signed on HIV-1 gp120 consensus B sequence):
the inner forward V3S2 5’ CAGCACAGTACAAT-
GTACACA 3’ primer (nt: 630-650) and V3AS5
(Figure 1, Table 1). Amplification conditions
were: one cycle at 93°C for 12 min, 40 cycles
(93°C 30s, 51°C 30s, 72°C 50s) and a final step at
72°C for 10 min, using the following master mix:
5 ul of Taq Gold PE buffer 10X, 3 ul of 25 mM
MgCl2, 33.95 ul of DNase- and RNase-free bidis-
telled water, 0.75 ul of 10 uM primers, 0.8 ul of
12.5 mM dNTPs, 0.75 ul of Taq (5 u/ul) in a total
volume of 45 ul.
The PCR product was purified by Microcon PCR
purification kit (Millipore). Negative and positive
control samples were included in each PCR run
to exclude false-positive and false-negative reac-
tions.
PCR-products were then sequenced by using the
BigDye terminator v.3.1 cycle sequencing kit
(Applied-Biosystems), and an automated se-
quencer (ABI-3100). Four different overlapping
sequence-specific primers were used to ensure
the coverage of the V3-sequence by at least two
sequence segments (Figure 1). The sequencing
conditions were: one cycle 96°C 3 min, 25 cycles
(96°C 30s, 50°C 10s, 60°C 4 min) and the follow-
ing primers were used: V3S6 5’CTGTTAAATG-
GCAGTCTAGC 3’, V3S5 5’ GTTAAATGGCAGTC-
TAGCAG 3’, V3AS1 5’ GAAAAATTCCCCTCCA-
CAATT 3’ and V3AS3bis 5’ CAATTTCTGGGTCC-
CCTC 3’.
For each sample, HIV-1 subtype was determined
by using the geno2pheno algorithm and con-
firmed by phylogenetic analysis of V3-containing
nucleotide sequences (Svicher et al., 2010).
Phylogenetic analysis was also used to identify
potential cross-contaminations during the se-
quencing process.
Genotypic prediction of viral tropism. HIV-1 co-
receptor usage was inferred from the V3 nu-
cleotide sequence by using the geno2pheno algo-
rithm available at http://coreceptor.bioinf.mpi-
inf.mpg.de/. 
The system is based on a support vector machine
methodology that has been trained with a set of
V3 nucleotide sequences with known phenotyp-
ic tropism. The tool can also analyze amino-acid
mixtures deduced from degenerate base calls. The
result of the interpretation is given as a quanti-
tative value, the false positive rate (FPR), that de-
fines the probability of classifying an R5 virus
falsely as X4. HIV-1 co-receptor usage was in-
ferred by using both the clonal version of
geno2pheno set at FPR of 20%.
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TABLE 1 - Overview of the primer and cycling conditions for V3 PCR.
PCR Nested PCR
Sense primer 5’- CCAATTCCCATACATTATTGT -3’ 5’- CAGCACAGTACAATGTACACA -3’
Antisense primer 5’-CTTCTCCAATTGTCCCTCA- 3’ 5’-CTTCTCCAATTGTCCCTCA-3’
PCR settings 12 min 93°C, 1 cycle 12 min 93°C, 1 cycle
30s 93°C 30s 93°C
30s 50°C 40 cycles 30s 51°C 40 cycles
40s 72°C 40s 72°C
10 min 72°C 1 cycle 10 min 72°C 1 cycle
PCR, polymerase chain reaction.
} }
RESULTS
Patient’s characteristics. This study included a
total of 53 HIV-1 infected patients (52 HAART-
treated and 1 drug-naïve). 
Among them, 49 (94.3%) had undetectable HIV-
1 RNA (<50 copies/ml) and 2 had low plasma
HIV-1 RNA (130 and 580 copies/ml). 
For the remaining 2 patients, plasma HIV-1 RNA
was 6,406 and 15,432 copies/ml, respectively.
Eight (all with plasma HIV-1 RNA <50 copies/ml)
were included in the first phase and 45 in the sec-
ond phase of the DIVA study. 
Their clinical and viro-immunological character-
istics are shown in Table 2.
At the time of sample collection, the median CD4
cell count was 495 (IQR:390-730) cells/ul, and the
median total HIV-DNA (available for 42 out of 53
patients) was 638 (IQR:253-1,183) 106 PBMCs.
The large majority of patients harbored HIV-1 B
subtype (N = 49, 92.4%). 
Other non-B subtypes were: G (N = 3, 5.7%), and
C (N = 1, 1.9%).
Standardization of genotypic tropism testing
on proviral DNA. The DIVA study was specifi-
cally designed to set up a standardized method-
ology for V3 sequencing on proviral DNA for the
routine clinical diagnostic-laboratory. In order to
achieve this goal, the study was articulated in 2
validation procedures whose results are report-
ed as follows.
Results from the first phase. The first phase of
the DIVA study was aimed at setting up and cross-
validating the methodology of V3 sequencing on
proviral DNA among the 5 reference centers en-
rolled in the project. For this phase, PBMCs from
8 HAART-treated patients with HIV-1 RNA <50
copies/ml from at least 6 months (median [IQR]
time under virological suppression: 2 [3-4] years)
were collected. 
The median HIV-1 DNA was 391 (IQR: 256-807)
copies/106 PBMCs (range 93-1,044 copies/106
PBMCs). There was complete agreement in tro-
pism designation for all the 8 samples analyzed
by the four reference centers (5 and 5 samples
were scored as R5 and X4/DM, respectively). The
median similarity among V3 sequences was 100%
(IQR: 95%-100%). These results prompted the im-
plementation of the second phase of the DIVA
study.
Results from the second phase. The second
phase was aimed at validating and sharing the
methodology for tropism determination on provi-
ral DNA among all the 12 local virological cen-
ters involved in the project. A total of 60 PBMCs
aliquots from 45 HIV-infected patients were col-
lected by the 5 reference centers and sent to local
virological centers. All the samples sent to local
centers were successfully amplified by the refer-
ence centers. Quantification of HIV-1 DNA
(known for 35/45 patients) reported a median
(IQR) HIV DNA: 598 (IQR:252-1,203) copies/106
PBMCs.
Fifty-six out of 60 (93.3%) PBMCs samples were
successfully amplified by the local centers. The
median HIV-1 DNA quantification for the not-
amplifiable samples (available for 3/4 of them, all
subtypes B) was 73, 212, 1,223 copies/106 PBMCs,
respectively.
Tropism prediction obtained at the local and ref-
erence center was concordant for 54/56 (96.4%)
samples. Genotypic tropism testing on proviral
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TABLE 2 - Patients’ characteristics.
Number of patients 53
Male sex, number (%) 27 (65.8)
HIV-1 subtype, number (%)
B 49 (92.4)
G 3 (5.7)
C 1 (1.9)
Total HIV-DNA (copies/106 cells)
Median 638
Interquartile range 253-1183
CD4 cell count (cells/ul)
Median 495
Interquartile range 390-730
Nadir CD4 cell count (cells/ul)
Median 200
Interquartile range 105-348
Third drug, number (%)
PI- treated 25 (62.5)
NNRTI-treated 15 (37.5)
N. of previous regimens
Median 2
Interquartile range 1-3
DNA reported 33/54 (61.1%) R5 V3 sequences
and 21/54 (38.9%) X4 V3 sequences. 
The amino acid similarity and the difference in
the FPR between V3 sequences obtained by the
reference and local virological center were also
estimated. The median (IQR) amino acid simi-
larity was 95.7% (94.3%-98.6%), and the median
difference (IQR) of FPR was 1.1 (-1.7;7.8). For
65.9% of samples, amino acid differences in V3
sequences obtained by local and reference cen-
ter were due to the presence of at least 1 degen-
erate codon.
These results support the reliability of the
methodology for V3 sequencing on proviral DNA
set up in the framework of the DIVA study. 
DISCUSSION
The DIVA study has allowed to set up a method-
ology for V3 sequencing on proviral DNA shared
by Italian scientific community. The availability
of a rapid and not expensive assay, as genotypic
testing, to determine tropism in proviral DNA is
crucial to optimize the use of CCR5 antagonists
in clinical practice. Our results are in line with
other European studies, and support the routine
use of genotypic tropism testing on proviral-DNA
in patients with suppressed plasma HIV-1 RNA
candidate to CCR5-antagonist treatment.
Indeed, a recent study has evaluated the per-
formances of genotypic tropism testing in provi-
ral DNA using Toulouse Tropism Test phenotyp-
ic assay as reference in patients with primary
HIV-1 infection (Raymond et al., 2010). Genotypic
tropism testing on proviral DNA using geno2phe-
no algorithm at a FPR of 10% and 5.75% was
96.3% and 100% concordant with phenotypic
testing, respectively (Raymond et al., 2010).
Another recent study has shown a 85% concor-
dance of genotypic tropism testing on proviral
DNA with phenotypic tropism testing (at both 10
and 5% FPRs), supporting that genotypic tropism
testing in proviral DNA offers a promising ap-
proach for tropism prediction in clinical practice
(Verhofstede C et al., 2011). Thus, as supported
by the European Guidelines for the clinical man-
agement of tropism determination, the possibili -
ty to perform tropism testing on proviral DNA
even during suppressed viremia can facilitate the
use of CCR5 inhibitors as part of switching, sim-
plification, or intensification strategies. In this
light, the DIVA study has answered to a precise
unmet medical need.
Several studies have investigated HIV-1 tropism
in proviral DNA in HIV-1 infected viremic pa-
tients (Frange et al., 2009; Verhofstede et al.,
2009; Seclen et al., 2010; Swenson et al., 2010). In
general, these studies, mostly run in patients with
detectable viremia, show a higher prevalence of
X4-predicted sequences in proviral DNA than in
RNA samples. It is unknown whether this is an
overestimation of X4 variants in proviral DNA
compared to plasma, due to the presence of less-
or non-viable viral genomes that accumulated
over the years without being represented in plas-
ma (that is by definition enriched only with repli-
cating, viable viral genomes). This situation may
be typical of X4 viruses that, despite being ran-
domly generated while virus replicates, are less
represented in plasma than R5 viruses during
the major part of the course of the disease.
Specific studies are thus needed in order to bet-
ter define the pathogenetic and clinical relevance
of X4 species detected in proviral DNA, and to
establish X4 frequency thresholds that can be
tolerated in respect of effective CCR5 antagonist
treatment. 
In this study, we reported 33/54 (61.1%) R5 and
21/54 (38.9%) X4 V3 sequences using a thresh-
old of FPR=20%, and 38/54 (70.4%) R5 and 16/34
(29.6%) X4 sequences using a threshold of
FPR=10%. All these sequences were obtained
from patients (all but 4) with undetectable
viremia. The proportion of R5-using viruses in
proviral DNA is consistent with two recent stud-
ies where a threshold of FPR=10% has been used.
In particular, by analyzing a subset of 78 and 140
HAART-treated patients with suppressed viremia,
R5 using viruses in proviral DNA were detected in
66.0% (Seclen et al., 2010) and 70.0% (Soulie et
al., 2010) of patients analyzed, corroborating the
critical role played by R5-tropic viruses in HIV
pathogenesis. These 2 studies also showed a very
low rate of switches from R5 to X4 tropism de-
spite a median follow up >3 years of suppressive
HAART, thus supporting the reliability of the
genotypic tropism testing in proviral DNA.
The study by Soulie et al., 2010 also highlighted
a correlation between X4 tropism and nadir CD4
cell count. Indeed, X4-using viruses (although de-
tected in all the nadir CD4 cell count categories
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analyzed) were found with the highest prevalence
in patients with nadir CD4 cell count <100
cells/ul. Consistent with these results, another
study showed that the nadir CD4 cell count was
the only baseline characteristic correlated with a
switch from R5 to X4 tropism in proviral DNA
(Saracino et al., 2009). In our study, patients with
X4-using strains are characterized by a nadir CD4
cell count lower than patients with CCR5-using
strains, even if not statistically significant (148
[89-299] vs 243 [140-374], p=0.23).
Tropism prediction between local virological cen-
ter and reference center was concordant for
54/56 (96.4%) samples. The 2 discordant sam-
ples had a total HIV-1 DNA <13 copies/106
PBMCs and 3,497 copies/106 PBMCs, respec-
tively. For the former, the discordance in tropism
prediction can be explained by stochastic errors
in sampling and amplification in the setting of
low viral input. For the latter, the discordance
can be explained by the high degree of env ge-
netic variability and quasispecies heterogeneity
observed in proviral DNA acting as an archive of
all the variants present in an infected patient dur-
ing the natural history of the infection (Abbate et
al., 2010; Rozera et al., 2009). 
The methodology of V3 sequencing used in this
study is based on a single amplification of the V3
region. The use of single versus triplicate geno-
typic analysis is still matter of debate. Indeed,
preliminary data from clinical trials have sug-
gested that genotypic analysis in triplicate may
increase the detection of X4-tropic viruses
(Swenson et al., 2010). 
A recent study has evaluated the added value of
triplicate versus single testing on genotypic tro-
pism prediction in routine clinical practice in
both plasma and proviral DNA samples. The au-
thors found that the triplicate testing resulted in
an enhanced detection of X4-variants only in a
small percentage of patients, thus supporting the
urgent need to compare single versus triplicate
amplification procedures in relation to clinical
outcome data (Symons et al., 2011). Further stud-
ies are necessary to evaluate the clinical signifi-
cance of triplicate versus single genotypic analy-
sis for tropism prediction. 
In conclusion, we showed high concordance in
the genotypic approach for tropism-prediction
on proviral-DNA among different virological cen-
ters throughout Italy. Our results support the fea-
sibility and consistency of genotypic tropism test-
ing on proviral DNA as a laboratory tool poten-
tially assisting selection of patients with sup-
pressed plasma HIV-1 RNA candidate to CCR5-
antagonist treatment.
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